ASTH — Astrana Health Cashflow Statement
0.000.00%
- $1.29bn
- $1.21bn
- $2.03bn
- 82
- 62
- 13
- 51
Annual cashflow statement for Astrana Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 122 | 49.3 | 50.5 | 57.8 | 49.9 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | -98.7 | 29.6 | 31.3 | 28.5 | 42.2 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 10.8 | -20.1 | -9.58 | -23.4 | -63.6 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 46.2 | 70.3 | 82.1 | 68.2 | 52.2 |
Capital Expenditures | -1.16 | -19.2 | -22.9 | -28.5 | -8.03 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 96.7 | 35.8 | 15.8 | -37 | -184 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 95.5 | 16.5 | -7.11 | -65.5 | -192 |
Financing Cash Flow Items | -1.04 | -2.15 | -4.61 | -5.01 | -6.01 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -51.7 | -47.7 | -20.1 | 3.42 | 135 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 90 | 39.1 | 54.9 | 6.13 | -5.05 |